Friday's Winners & Losers: Research In Motion
Micron shed 88 cents, or 12.6%, to $6.11 after it posted a wider-than-expected quarterly loss. Micron lost $236 million in its third quarter, or 30 cents a share, worse than analysts' expectation of a loss of 28 cents a share.
Shares of Research In Motion were down $4.31, or 3.5%, to $119.14, two days after the company disappointed Wall Street with its first-quarter earnings report and outlook. RIM's earnings for the first quarter fell a penny shy of analysts' estimates and the company guided revenue for the current quarter in the range of $2.55 billion to $2.65 billion, lower than Street expectations of $2.43 billion.
Health stocks closed out the week on a bright note, outperforming the broader markets Friday and airing scattered business, regulatory and clinical news.Exelixis (EXEL) and GlaxoSmithKline (GSK) said early Friday that they will not extend their cancer compound collaboration. Under the terms of the six-year agreement that's wrapping up, Glaxo will retain the option to further develop one of five cancer compounds in Exelixis' early clinical development. Exelixis has the right to develop and commercialize those not selected by Glaxo. Exelixis shares fell 13 cents, or 2.5%, to $5.09, while Glaxo shares edged down 36 cents, or 0.8%, to $43.94. Small-cap stocks were taking on losses alongside the major indices as bears controlled the market action Friday. The Russell 2000 was roughly flat at 698.46, and the S&P SmallCap 600 edged down 0.1% to 370.05. Shares of Azz (AZZ) surged 22% higher to $39.35 on better-than-expected fiscal first-quarter earnings. The Fort Worth, Texas-based electrical equipment manufacturer earned $10.1 million, or 82 cents a share, up from $4.1 million, or 34 cents a share, in the same quarter last year. Analysts were looking for earnings of 54 cents a share. Azz is forecasting for fiscal 2009 earnings of $2.95 to $3.05 a share. Analysts are expecting full-year EPS of $2.43, according to Thomson Reuters data.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV